Clinical Research Directory
Browse clinical research sites, groups, and studies.
PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression
Sponsor: Peking University First Hospital
Summary
This project uses HER2 protein as the target group of radiodrugs to explore the diagnostic efficacy, safety and metabolic characteristics of 68Ga-Her2-affibody in the expression status of HER2, aiming to provide a new imaging method for the determination of HER2 status in breast cancer At the same time, it also provides new methods and means for early diagnosis, accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and provides scientific basis for precise treatment of malignant tumors.
Official title: A Study to Evaluate 68Ga-Her2-affibody PET/CT Imaging of Her2 Expression in Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-05-28
Completion Date
2025-08-30
Last Updated
2024-12-18
Healthy Volunteers
No
Conditions
Interventions
68Ga-Her2-affibody
68Ga-Her2-affibody is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Locations (1)
Peking University First Hospital
Beijing, Beijing Municipality, China